Global HIV specialist firm ViiV Healthcare says it has extended the overall country coverage of its existing license agreement for its adults formulation of dolutegravir to the Medicines Patent Pool (MPP) to cover all lower middle income countries (LMICs).
ViiV, which is majority-owned by UK major GlaxoSmithKline (LSE: GSK), with US pharma giant Pfizer (NYSE: PFE) and Japan’s Shionogi (TYO: 4507) as shareholders, notes that the existing license agreement already covers all low income, least developed and all sub-Saharan African countries. This extension to include all remaining LMICs means that more than 94% of adults living with HIV in the developing world are now covered by the license agreement.
Particular relevance for Armenia, Moldova, Morocco and Ukraine
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze